Trial reportJornal brasileiro de nefrologia
Impact of Curcuma longa L. extract supplementation on the gut microbiota of hemodialysis patients.
Trial report in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe impact of curcumin on the gut microbiota of chronic kidney disease (CKD) patients is not well known. The aim of this study was to evaluate the effect of Curcuma longa L. on the gut microbiota of CKD patients undergoing hemodialysis (HD).
methodsThis was a secondary analysis of data from a randomized, double-blind, placebo-controlled trial. Patients received 100 mL of orange juice, 12 grams of carrot, and 2.5 grams of Curcuma longa L. three times a week after the HD session (Curcuma group) or the same juice without added curcumin (control group) for 12 weeks. The fecal microbiota composition was estimated using short-read sequencing of the V4 region of the 16S rRNA gene on the Illumina platform.
resultsEleven patients participated in this study, five in the curcumin group (66.7% male, 59 ± 16.7 years old, HD vintage of 97 ± 62.6 months, BMI 25.3 ± 2.9 kg/m2) and six in the control group (60% male, 57.5 ± 12.5 years old, HD vintage of 48.3 ± 32.2 months, BMI 25.2 ± 3.1 kg/m2). Supplementation with Curcuma longa L. extract did not modify alpha biodiversity or the taxonomic composition of individuals at the phylum, family, and genus levels.
conclusionSupplementation with 2.5 g of Curcuma longa L. extract three times per week for 12 weeks was inefficient in modulating the gut microbiota of CKD patients undergoing HD. These results should be interpreted taking into account the small sample size, and future studies with larger cohorts are encouraged.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.